PepGen Inc. (PEPG)
NASDAQ: PEPG · Real-Time Price · USD
1.150
-0.130 (-10.16%)
Jun 27, 2025, 4:00 PM - Market closed
PepGen Employees
PepGen had 81 employees as of December 31, 2024. The number of employees increased by 17 or 26.56% compared to the previous year.
Employees
81
Change (1Y)
17
Growth (1Y)
26.56%
Revenue / Employee
n/a
Profits / Employee
-$1,261,272
Market Cap
37.63M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 81 | 17 | 26.56% |
| Dec 31, 2023 | 64 | 19 | 42.22% |
| Dec 31, 2022 | 45 | 14 | 45.16% |
| Dec 31, 2021 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PEPG News
- 4 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen - GlobeNewsWire
- 5 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPG - PRNewsWire
- 12 days ago - Shareholders who lost money on PepGen Inc. (NASDAQ: PEPG) Should Contact Wolf Haldenstein - GlobeNewsWire
- 18 days ago - PEPGEN INC. (NASDAQ: PEPG) INVESTOR ALERT Investors With Large Losses in PepGen Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - GlobeNewsWire
- 4 weeks ago - PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate - Benzinga
- 4 weeks ago - PepGen to discontinue development of experimental Duchenne therapy; shares drop - Reuters
- 4 weeks ago - PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update - Business Wire
- 5 weeks ago - PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer - Business Wire